US9228186B2
(en)
|
2002-11-14 |
2016-01-05 |
Thermo Fisher Scientific Inc. |
Methods and compositions for selecting siRNA of improved functionality
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
EA015676B1
(ru)
|
2006-05-11 |
2011-10-31 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии гена pcsk9
|
US8598333B2
(en)
*
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
AU2009241591A1
(en)
*
|
2008-01-31 |
2009-11-05 |
Alnylam Pharmaceuticals, Inc. |
Optimized methods for delivery of DSRNA targeting the PCSK9 gene
|
EP2712926A2
(en)
|
2008-03-05 |
2014-04-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
NZ588583A
(en)
|
2008-04-15 |
2012-08-31 |
Protiva Biotherapeutics Inc |
Novel lipid formulations for nucleic acid delivery
|
JP5529142B2
(ja)
|
2008-09-25 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法
|
SI2937418T1
(en)
|
2008-10-20 |
2018-02-28 |
Alnylam Pharmaceuticals, Inc. |
Compounds and procedures for inhibiting the expression of transthyretin
|
KR20220150995A
(ko)
*
|
2008-11-10 |
2022-11-11 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
JP5855462B2
(ja)
|
2008-12-10 |
2016-02-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
GNAQを標的としたdsRNA組成物および発現を阻害するための方法
|
WO2010105209A1
(en)
*
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
US20100285112A1
(en)
*
|
2009-05-05 |
2010-11-11 |
Tatiana Novobrantseva |
Methods of delivering oligonucleotides to immune cells
|
KR102205886B1
(ko)
|
2009-06-10 |
2021-01-21 |
알닐람 파마슈티칼스 인코포레이티드 |
향상된 지질 조성물
|
US9051567B2
(en)
*
|
2009-06-15 |
2015-06-09 |
Tekmira Pharmaceuticals Corporation |
Methods for increasing efficacy of lipid formulated siRNA
|
KR20120050429A
(ko)
|
2009-06-15 |
2012-05-18 |
알닐람 파마슈티칼스 인코포레이티드 |
Pcsk9 유전자를 표적으로 하는 지질 제형된 dsrna
|
WO2011000107A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Novel lipid formulations for delivery of therapeutic agents to solid tumors
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
CN107519133A
(zh)
|
2009-09-15 |
2017-12-29 |
阿尔尼拉姆医药品有限公司 |
脂质配制的组合物及抑制Eg5和VEGF基因的表达的方法
|
WO2011038031A1
(en)
|
2009-09-22 |
2011-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting sirna agents
|
JP5551780B2
(ja)
|
2009-09-22 |
2014-07-16 |
メディカゴ インコーポレイテッド |
植物由来のタンパク質を調製する方法
|
US9101643B2
(en)
*
|
2009-11-03 |
2015-08-11 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
|
ES2713852T3
(es)
|
2009-12-01 |
2019-05-24 |
Translate Bio Inc |
Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas
|
WO2011075656A1
(en)
*
|
2009-12-18 |
2011-06-23 |
The University Of British Columbia |
Methods and compositions for delivery of nucleic acids
|
US8846631B2
(en)
|
2010-01-14 |
2014-09-30 |
Regulus Therapeutics Inc. |
MicroRNA compositions and methods
|
US10077232B2
(en)
|
2010-05-12 |
2018-09-18 |
Arbutus Biopharma Corporation |
Cyclic cationic lipids and methods of use
|
WO2011141705A1
(en)
|
2010-05-12 |
2011-11-17 |
Protiva Biotherapeutics, Inc. |
Novel cationic lipids and methods of use thereof
|
WO2012000104A1
(en)
*
|
2010-06-30 |
2012-01-05 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
BR112013000244A2
(pt)
|
2010-07-06 |
2016-05-17 |
Novartis Ag |
lipossomas com lipídeos apresentando pka vantajoso para administração de rna
|
SI2591114T1
(sl)
|
2010-07-06 |
2016-10-28 |
Glaxosmithkline Biologicals S.A. |
Imunizacija velikih sesalcev z majhnimi odmerki RNA
|
LT3243526T
(lt)
|
2010-07-06 |
2020-02-10 |
Glaxosmithkline Biologicals S.A. |
Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
|
WO2012016188A2
(en)
*
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP2606134B1
(en)
|
2010-08-17 |
2019-04-10 |
Sirna Therapeutics, Inc. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
WO2012027467A1
(en)
|
2010-08-26 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
SI3970742T1
(sl)
|
2010-08-31 |
2022-08-31 |
Glaxosmithkline Biologicals S.A. |
Pegilirani liposomi za dostavo RNA, ki kodira imunogen
|
US8466122B2
(en)
|
2010-09-17 |
2013-06-18 |
Protiva Biotherapeutics, Inc. |
Trialkyl cationic lipids and methods of use thereof
|
CN103167866B
(zh)
|
2010-09-20 |
2015-09-23 |
瑟纳治疗公司 |
用于寡核苷酸递送的新型低分子量阳离子脂质
|
DK3590949T3
(da)
|
2010-10-01 |
2022-07-11 |
Modernatx Inc |
Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf
|
EP3520813B1
(en)
*
|
2010-10-11 |
2023-04-19 |
GlaxoSmithKline Biologicals S.A. |
Antigen delivery platforms
|
US9029590B2
(en)
|
2010-10-21 |
2015-05-12 |
Sirna Therapeutics, Inc. |
Low molecular weight cationic lipids for oligonucleotide delivery
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
US9067882B2
(en)
|
2010-11-05 |
2015-06-30 |
Sirna Therapeutics, Inc. |
Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
TWI620816B
(zh)
|
2011-03-23 |
2018-04-11 |
苜蓿股份有限公司 |
植物衍生蛋白回收方法
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9687529B2
(en)
*
|
2011-05-05 |
2017-06-27 |
Duke University |
Method of controlling coagulation
|
WO2012159164A1
(en)
*
|
2011-05-23 |
2012-11-29 |
Phylogica Limited |
Method of determining, identifying or isolating cell-penetrating peptides
|
KR20200084048A
(ko)
|
2011-06-08 |
2020-07-09 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
EP3388068A1
(en)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Composition and methods for inhibition of expression of protein c (proc) genes
|
AU2012272970A1
(en)
|
2011-06-21 |
2014-02-06 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
|
RU2631805C2
(ru)
*
|
2011-06-21 |
2017-09-26 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
DK2751270T3
(en)
|
2011-08-29 |
2018-10-29 |
Ionis Pharmaceuticals Inc |
OLIGOMER-CONJUGATE COMPLEXES AND THEIR USE
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
SG10201602654SA
(en)
|
2011-10-03 |
2016-05-30 |
Moderna Therapeutics Inc |
Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
|
EP3301177B1
(en)
|
2011-11-18 |
2020-03-25 |
Alnylam Pharmaceuticals, Inc. |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
DK3988537T1
(da)
|
2011-12-07 |
2022-05-23 |
Alnylam Pharmaceuticals Inc |
Bionedbrydelige lipider til afgivelse af aktive midler
|
JP6305343B2
(ja)
*
|
2011-12-07 |
2018-04-04 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性薬剤の送達のための分岐アルキルおよびシクロアルキルを末端とする生分解性脂質
|
WO2013090648A1
(en)
*
|
2011-12-16 |
2013-06-20 |
modeRNA Therapeutics |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
US9035039B2
(en)
|
2011-12-22 |
2015-05-19 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing SMAD4
|
RU2020111326A
(ru)
*
|
2012-02-24 |
2020-04-29 |
Протива Байотерапьютикс Инк. |
Триалкил катионные липиды и способы их использования
|
US10501513B2
(en)
*
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
JP2015516143A
(ja)
|
2012-04-02 |
2015-06-08 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
ヒト疾患に関連するタンパク質の産生のための修飾ポリヌクレオチド
|
JP2015518705A
(ja)
|
2012-04-02 |
2015-07-06 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9303079B2
(en)
|
2012-04-02 |
2016-04-05 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
CA2870941C
(en)
|
2012-04-19 |
2021-05-25 |
Sirna Therapeutics, Inc. |
Diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013170146A1
(en)
|
2012-05-10 |
2013-11-14 |
Uab Research Foundation |
Methods and compositions for modulating mir-204 activity
|
EP3884949A1
(en)
|
2012-06-08 |
2021-09-29 |
Translate Bio, Inc. |
Pulmonary delivery of mrna to non-lung target cells
|
EP2859102A4
(en)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
NUCLEASE RESISTANT POLYNUCLEOTIDES AND USES THEREOF
|
US9415109B2
(en)
|
2012-07-06 |
2016-08-16 |
Alnylam Pharmaceuticals, Inc. |
Stable non-aggregating nucleic acid lipid particle formulations
|
US9512456B2
(en)
|
2012-08-14 |
2016-12-06 |
Modernatx, Inc. |
Enzymes and polymerases for the synthesis of RNA
|
US20140120157A1
(en)
|
2012-09-19 |
2014-05-01 |
Georgetown University |
Targeted liposomes
|
AU2013380825B2
(en)
*
|
2012-10-16 |
2017-07-20 |
Biomics Biotechnologies Co., Ltd. |
Lipidosome preparation, preparation method and application thereof
|
LT2922554T
(lt)
|
2012-11-26 |
2022-06-27 |
Modernatx, Inc. |
Terminaliai modifikuota rnr
|
CN104854242B
(zh)
|
2012-12-05 |
2018-03-16 |
阿尔尼拉姆医药品有限公司 |
PCSK9 iRNA组合物及其使用方法
|
AU2013355258A1
(en)
*
|
2012-12-07 |
2015-06-11 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
EP2946014A2
(en)
|
2013-01-17 |
2015-11-25 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
US20160024181A1
(en)
*
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
KR20210122917A
(ko)
|
2013-03-14 |
2021-10-12 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
CN114015692A
(zh)
|
2013-03-14 |
2022-02-08 |
阿尔尼拉姆医药品有限公司 |
补体组分C5 iRNA组合物及其使用方法
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
LT2970456T
(lt)
|
2013-03-14 |
2021-08-10 |
Translate Bio, Inc. |
Būdai ir kompozicijos, skirti mrnr koduojamų antikūnų pristatymui
|
WO2014152031A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Ribonucleic acid purification
|
WO2014172045A1
(en)
*
|
2013-03-15 |
2014-10-23 |
The University Of British Columbia |
Lipid nanoparticles for transfection and related methods
|
EP2968147A4
(en)
*
|
2013-03-15 |
2017-02-22 |
The Penn State Research Foundation |
Acid stable liposomal compositions
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
RS57316B1
(sr)
|
2013-03-15 |
2018-08-31 |
Translate Bio Inc |
Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
NZ631512A
(en)
|
2013-05-01 |
2016-10-28 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating apolipoprotein (a) expression
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
HUE038146T2
(hu)
|
2013-05-22 |
2018-09-28 |
Alnylam Pharmaceuticals Inc |
Serpina1 IRNS készítmények és eljárások alkalmazásukra
|
EP2999786A1
(en)
|
2013-05-22 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Tmprss6 irna compositions and methods of use thereof
|
RS62529B1
(sr)
|
2013-07-11 |
2021-11-30 |
Modernatx Inc |
Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
|
WO2015011633A1
(en)
|
2013-07-23 |
2015-01-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for delivering messenger rna
|
WO2015034928A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
CA2921161A1
(en)
*
|
2013-09-24 |
2015-04-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for the manufacture of lipid nanoparticles
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052511A4
(en)
|
2013-10-02 |
2017-05-31 |
Moderna Therapeutics, Inc. |
Polynucleotide molecules and uses thereof
|
AU2014329452B2
(en)
|
2013-10-03 |
2019-06-20 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
EA201992208A1
(ru)
|
2013-10-22 |
2020-07-31 |
Транслейт Био, Инк. |
ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
|
MX2016005237A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Terapia de acido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa.
|
JP6893785B2
(ja)
|
2013-10-22 |
2021-06-23 |
トランスレイト バイオ, インコーポレイテッド |
mRNAのCNS送達及びその使用方法
|
EA201690576A1
(ru)
|
2013-10-22 |
2016-10-31 |
Шир Хьюман Дженетик Терапис, Инк. |
Липидные композиции для доставки матричной рнк
|
CN110003066B
(zh)
|
2013-11-18 |
2021-09-03 |
阿克丘勒斯治疗公司 |
用于rna递送的可电离的阳离子脂质
|
EP3985118A1
(en)
|
2013-11-22 |
2022-04-20 |
MiNA Therapeutics Limited |
C/ebp alpha short activating rna compositions and methods of use
|
CA3107872A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
EP3093283B1
(en)
*
|
2014-01-09 |
2018-12-19 |
Eisai R&D Management Co., Ltd. |
Cationic lipid
|
EA201691587A1
(ru)
|
2014-02-11 |
2017-01-30 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ КЕТОГЕКСОКИНАЗЫ (KHK) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2015130584A2
(en)
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
CN106659803A
(zh)
|
2014-04-23 |
2017-05-10 |
摩登纳特斯有限公司 |
核酸疫苗
|
WO2015164773A1
(en)
|
2014-04-25 |
2015-10-29 |
Shire Human Genetic Therapies, Inc. |
Methods for purification of messenger rna
|
EP3137476B1
(en)
|
2014-04-28 |
2019-10-09 |
Ionis Pharmaceuticals, Inc. |
Linkage modified oligomeric compounds
|
KR20200102553A
(ko)
|
2014-05-01 |
2020-08-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법
|
RU2703411C2
(ru)
|
2014-05-01 |
2019-10-16 |
Ионис Фармасьютикалз, Инк. |
Композиции и способы модулирования экспрессии пкп
|
EP3608406B1
(en)
|
2014-05-01 |
2023-02-15 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating complement factor b expression
|
PT3137605T
(pt)
|
2014-05-01 |
2020-12-18 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão de angiopoietina de tipo 3
|
RU2016144908A
(ru)
|
2014-05-02 |
2018-06-05 |
Серени Терапеутикс Холдинг Са |
Маркеры hdl-терапии
|
WO2015179693A1
(en)
|
2014-05-22 |
2015-11-26 |
Isis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
CA2949106C
(en)
|
2014-05-30 |
2023-10-24 |
Shire Human Genetic Therapies, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
WO2015188194A1
(en)
*
|
2014-06-06 |
2015-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds
|
CN106795142B
(zh)
|
2014-06-24 |
2022-11-04 |
川斯勒佰尔公司 |
用于递送核酸的立体化学富集组合物
|
PT3766916T
(pt)
|
2014-06-25 |
2022-11-28 |
Acuitas Therapeutics Inc |
Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
|
JP6782171B2
(ja)
|
2014-07-02 |
2020-11-11 |
シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド |
メッセンジャーrnaのカプセル化
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2016014846A1
(en)
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
DK3185957T3
(da)
|
2014-08-29 |
2022-08-29 |
Alnylam Pharmaceuticals Inc |
Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
|
EP3191591A1
(en)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
US10889812B2
(en)
|
2014-10-24 |
2021-01-12 |
University Of Maryland, Baltimore |
Short non-coding protein regulatory RNAs (sprRNAs) and methods of use
|
EP3212794B1
(en)
*
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
US9943595B2
(en)
|
2014-12-05 |
2018-04-17 |
Translate Bio, Inc. |
Messenger RNA therapy for treatment of articular disease
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
TWI699354B
(zh)
|
2014-12-26 |
2020-07-21 |
日商衛材R&D企管股份有限公司 |
陽離子性脂質
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
AU2016233135B2
(en)
|
2015-03-19 |
2021-07-08 |
Translate Bio, Inc. |
mRNA therapy for pompe disease
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
JP6975641B2
(ja)
|
2015-04-13 |
2021-12-01 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
アンギオポエチン様3(ANGPTL3)iRNA組成物およびそれらの使用方法
|
WO2016176426A1
(en)
|
2015-04-28 |
2016-11-03 |
Duke University |
Thrombus imaging aptamers and methods of using same
|
CN108271386B
(zh)
|
2015-05-06 |
2022-07-15 |
阿尔尼拉姆医药品有限公司 |
因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法
|
EP3307316A1
(en)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
ES2917181T3
(es)
|
2015-07-10 |
2022-07-07 |
Ionis Pharmaceuticals Inc |
Moduladores de diacilglicerol aciltransferasa 2 (DGAT2)
|
KR20180031025A
(ko)
|
2015-07-31 |
2018-03-27 |
아크투루스 쎄라퓨틱스, 인크. |
약물 전달을 위한 다중 리간드 제제
|
DK3329002T3
(da)
|
2015-07-31 |
2021-01-11 |
Alnylam Pharmaceuticals Inc |
Transthyretin (ttr)-irna-sammensætninger og fremgangsmåder til anvendelse deraf til behandling eller forebyggelse af ttr-forbundne sygdomme
|
WO2017031232A1
(en)
|
2015-08-17 |
2017-02-23 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
EP3344769B1
(en)
|
2015-09-02 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (pd-l1) irna compositions and methods of use thereof
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
HUE057613T2
(hu)
|
2015-09-17 |
2022-05-28 |
Modernatx Inc |
Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
|
EP3353328A4
(en)
|
2015-09-24 |
2019-06-12 |
Ionis Pharmaceuticals, Inc. |
MODULATORS OF KRAS EXPRESSION
|
EP3355932B1
(en)
|
2015-10-02 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
EP3362555B1
(en)
|
2015-10-14 |
2021-01-13 |
Translate Bio, Inc. |
Modification of rna-related enzymes for enhanced production
|
RS63381B1
(sr)
|
2015-10-22 |
2022-08-31 |
Modernatx Inc |
Vakcine protiv respiratornih virusa
|
IL286515B2
(en)
|
2015-10-28 |
2024-02-01 |
Acuitas Therapeutics Inc |
Novel lipids and nanoparticle formulations of lipids for delivery of nucleic acids
|
BR122023026882A2
(pt)
|
2015-11-06 |
2024-01-23 |
Ionis Pharmaceuticals, Inc |
Uso de um composto oligomérico
|
WO2017079745A1
(en)
|
2015-11-06 |
2017-05-11 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
DK3376859T3
(da)
|
2015-11-18 |
2021-03-29 |
Provivi Inc |
Mikroorganismer til fremstilling af insektferomoner og relaterede forbindelser
|
AU2016368289C1
(en)
|
2015-12-07 |
2023-11-16 |
Genzyme Corporation |
Methods and compositions for treating a Serpinc1-associated disorder
|
AU2016366978B2
(en)
*
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
EP3387129A1
(en)
|
2015-12-10 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
DK3394030T3
(da)
|
2015-12-22 |
2022-03-28 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af midler
|
RS63135B1
(sr)
|
2015-12-23 |
2022-05-31 |
Modernatx Inc |
Postupci upotrebe polinukleotida koji kodiraju ox40 ligand
|
EP3400023A1
(en)
|
2016-01-10 |
2018-11-14 |
ModernaTX, Inc. |
Therapeutic mrnas encoding anti ctla-4 antibodies
|
WO2017127750A1
(en)
|
2016-01-22 |
2017-07-27 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
IL302398A
(en)
|
2016-03-03 |
2023-06-01 |
Univ Massachusetts |
End-capped linear double-stranded DNA for non-viral gene transfer
|
KR20230048446A
(ko)
|
2016-03-07 |
2023-04-11 |
애로우헤드 파마슈티컬스 인코포레이티드 |
치료용 화합물을 위한 표적화 리간드
|
WO2017177169A1
(en)
|
2016-04-08 |
2017-10-12 |
Rana Therapeutics, Inc. |
Multimeric coding nucleic acid and uses thereof
|
WO2017180917A2
(en)
|
2016-04-13 |
2017-10-19 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
WO2017194454A1
(en)
|
2016-05-09 |
2017-11-16 |
Astrazeneca Ab |
Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof
|
WO2017201332A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
ES2941411T3
(es)
|
2016-05-18 |
2023-05-22 |
Modernatx Inc |
Polinucleótidos que codifican interleucina-12 (IL12) y usos de los mismos
|
CA3024507A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding .alpha.-galactosidase a for the treatment of fabry disease
|
CN109640962B
(zh)
|
2016-05-18 |
2022-07-19 |
摩登纳特斯有限公司 |
编码松弛素的多核苷酸
|
US10993918B2
(en)
|
2016-05-18 |
2021-05-04 |
Modernatx, Inc. |
Polynucleotides encoding citrin for the treatment of Citrullinemia type 2
|
CN109890832B
(zh)
*
|
2016-06-06 |
2022-08-12 |
普罗维维股份有限公司 |
脂肪醇和脂肪醛的半生物合成产生
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
JP2019522047A
(ja)
|
2016-06-13 |
2019-08-08 |
トランスレイト バイオ, インコーポレイテッド |
オルニチントランスカルバミラーゼ欠損症治療のためのメッセンジャーrna療法
|
WO2017222016A1
(ja)
|
2016-06-24 |
2017-12-28 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
カチオン性脂質
|
JP7086870B2
(ja)
|
2016-06-30 |
2022-06-20 |
アルブータス・バイオファーマー・コーポレイション |
メッセンジャーrnaを送達するための組成物及び方法
|
PL3484524T3
(pl)
|
2016-07-15 |
2023-03-20 |
Ionis Pharmaceuticals, Inc. |
Związki i sposoby modulacji smn2
|
GB201614120D0
(en)
*
|
2016-08-18 |
2016-10-05 |
Univ Of Kwazulu-Natal |
pH-responsive lipids
|
SG10201913631TA
(en)
|
2016-08-19 |
2020-03-30 |
Curevac Ag |
Rna for cancer therapy
|
WO2018041921A1
(en)
|
2016-08-31 |
2018-03-08 |
Curevac Ag |
Mixing device for the production of a liquid nucleic acid composition
|
IL300869A
(en)
|
2016-09-02 |
2023-04-01 |
Arrowhead Pharmaceuticals Inc |
Ligands containing a targeting factor, preparations containing them and their uses
|
ES2924806T3
(es)
|
2016-09-02 |
2022-10-11 |
Dicerna Pharmaceuticals Inc |
Análogos de 4'-fosfato y oligonucleótidos que comprenden el mismo
|
EP3436054B2
(en)
|
2016-09-13 |
2022-07-27 |
Allergan, Inc. |
Stabilized non-protein clostridial toxin compositions
|
CN109982707A
(zh)
|
2016-09-16 |
2019-07-05 |
杜克大学 |
血管性血友病因子(vwf)靶向剂及其使用方法
|
EP3519578B1
(en)
|
2016-10-03 |
2021-12-22 |
Precision Nanosystems Inc |
Compositions for transfecting resistant cell types
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
RU2765874C2
(ru)
|
2016-10-26 |
2022-02-04 |
МОДЕРНАТиЭкс, ИНК. |
Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018104540A1
(en)
|
2016-12-08 |
2018-06-14 |
Curevac Ag |
Rnas for wound healing
|
CN110582304A
(zh)
|
2016-12-08 |
2019-12-17 |
库尔维科公司 |
用于治疗或预防肝脏疾病的rna
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
US10383952B2
(en)
|
2016-12-21 |
2019-08-20 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
US10526284B2
(en)
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
WO2018115525A1
(en)
|
2016-12-23 |
2018-06-28 |
Curevac Ag |
Lassa virus vaccine
|
US11141476B2
(en)
|
2016-12-23 |
2021-10-12 |
Curevac Ag |
MERS coronavirus vaccine
|
US11524066B2
(en)
|
2016-12-23 |
2022-12-13 |
CureVac SE |
Henipavirus vaccine
|
WO2018144775A1
(en)
|
2017-02-01 |
2018-08-09 |
Modernatx, Inc. |
Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides
|
WO2018146506A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Universitat Politècnica De València |
Therapeutic derivatives
|
EP3585417B1
(en)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Method of making a codon-optimized cftr mrna
|
PL3596041T3
(pl)
|
2017-03-15 |
2023-03-06 |
Modernatx, Inc. |
Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych
|
EP3596042B1
(en)
*
|
2017-03-15 |
2022-01-12 |
Modernatx, Inc. |
Crystal forms of amino lipids
|
CN110392577A
(zh)
|
2017-03-17 |
2019-10-29 |
库尔维科公司 |
用于组合抗癌疗法的rna疫苗和免疫检查点抑制剂
|
JOP20190215A1
(ar)
|
2017-03-24 |
2019-09-19 |
Ionis Pharmaceuticals Inc |
مُعدّلات التعبير الوراثي عن pcsk9
|
CA3050616A1
(en)
|
2017-03-24 |
2018-09-27 |
Curevac Ag |
Nucleic acids encoding crispr-associated proteins and uses thereof
|
WO2018187590A1
(en)
|
2017-04-05 |
2018-10-11 |
Modernatx, Inc. |
Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
BR112019021852A2
(pt)
|
2017-04-18 |
2020-06-02 |
Alnylam Pharmaceuticals, Inc. |
Agente de rnai e uma vacina contra hbv, uso ou método e kit para tratamento
|
WO2018200943A1
(en)
|
2017-04-28 |
2018-11-01 |
Acuitas Therapeutics, Inc. |
Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
WO2018213476A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
BR112019024258A2
(pt)
|
2017-05-17 |
2020-08-18 |
Provivi, Inc. |
Microorganismos yarrowia lipolytica recombinante e método para produzir um c6-c24 álcool graxo mono- ou poliinsaturado a partir de uma fonte endógena ou exógena de c6-c24 ácidograxo saturado
|
WO2018211038A1
(en)
|
2017-05-17 |
2018-11-22 |
Curevac Ag |
Method for determining at least one quality parameter of an rna sample
|
CA3063723A1
(en)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
|
WO2018213789A1
(en)
|
2017-05-18 |
2018-11-22 |
Modernatx, Inc. |
Modified messenger rna comprising functional rna elements
|
EP3630200A4
(en)
|
2017-05-31 |
2021-02-24 |
Arcturus Therapeutics, Inc. |
THERAPEUTICS FOR PHENYLKETONURIA
|
US11015204B2
(en)
|
2017-05-31 |
2021-05-25 |
Arcturus Therapeutics, Inc. |
Synthesis and structure of high potency RNA therapeutics
|
US11377643B2
(en)
|
2017-05-31 |
2022-07-05 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for glycogen storage disease type III
|
CN110997624A
(zh)
|
2017-06-06 |
2020-04-10 |
韦恩州立大学 |
与肉毒碱衍生的材料相关的方法和组合物
|
CN109030429B
(zh)
*
|
2017-06-09 |
2022-06-21 |
南京大学 |
一种可对活细胞内microRNA21进行原位成像的纳米放大自参比探针
|
EP3638292A1
(en)
|
2017-06-14 |
2020-04-22 |
ModernaTX, Inc. |
Polynucleotides encoding coagulation factor viii
|
WO2018231990A2
(en)
|
2017-06-14 |
2018-12-20 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
US10780183B2
(en)
|
2017-06-19 |
2020-09-22 |
Translate Bio, Inc. |
Messenger RNA therapy for the treatment of Friedreich's ataxia
|
CN111328287A
(zh)
|
2017-07-04 |
2020-06-23 |
库瑞瓦格股份公司 |
新型核酸分子
|
EP3652317A1
(en)
|
2017-07-13 |
2020-05-20 |
Alnylam Pharmaceuticals, Inc. |
Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
WO2019036030A1
(en)
|
2017-08-17 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
WO2019036670A2
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
EFFECTIVE MRNA VACCINES
|
US11602557B2
(en)
|
2017-08-22 |
2023-03-14 |
Cure Vac SE |
Bunyavirales vaccine
|
JP7275111B2
(ja)
|
2017-08-31 |
2023-05-17 |
モデルナティエックス インコーポレイテッド |
脂質ナノ粒子の生成方法
|
WO2019048645A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
STABILIZED COMPOSITIONS OF SMALL ACTIVATOR RNA (PARNA) FROM CEBPA AND METHODS OF USE
|
CA3075219A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Hnf4a sarna compositions and methods of use
|
JP2021508333A
(ja)
|
2017-09-19 |
2021-03-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
トランスサイレチン(ttr)媒介アミロイドーシスの治療用組成物及び方法
|
MX2020003995A
(es)
|
2017-10-19 |
2020-07-22 |
Curevac Ag |
Nuevas moleculas de acido nucleico artificiales.
|
CA3078971A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
RU2020117848A
(ru)
|
2017-11-08 |
2021-12-08 |
Куревак Аг |
Адаптиция последовательности phk
|
WO2019094702A1
(en)
|
2017-11-10 |
2019-05-16 |
Cocoon Biotech Inc. |
Ocular applications of silk-based products
|
WO2019099610A1
(en)
|
2017-11-16 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
EP3714054A1
(en)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
US11859215B2
(en)
|
2017-11-22 |
2024-01-02 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
WO2019104195A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
EP3714252B1
(en)
*
|
2017-11-22 |
2023-05-31 |
Beckman Coulter, Inc. |
Diluent preparation module und method for supplying such diluent
|
EP3714047A2
(en)
|
2017-11-22 |
2020-09-30 |
ModernaTX, Inc. |
Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
|
WO2019115635A1
(en)
|
2017-12-13 |
2019-06-20 |
Curevac Ag |
Flavivirus vaccine
|
CA3086343A1
(en)
|
2017-12-18 |
2019-06-27 |
Alnylam Pharmaceuticals, Inc. |
High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
|
US11167043B2
(en)
|
2017-12-20 |
2021-11-09 |
Translate Bio, Inc. |
Composition and methods for treatment of ornithine transcarbamylase deficiency
|
TWI801477B
(zh)
|
2017-12-27 |
2023-05-11 |
日商衛材R&D企管股份有限公司 |
陽離子性脂質
|
MA51523A
(fr)
|
2018-01-05 |
2020-11-11 |
Modernatx Inc |
Polynucléotides codant pour des anticorps anti-virus du chikungunya
|
CN111902537A
(zh)
|
2018-01-15 |
2020-11-06 |
Ionis制药公司 |
Dnm2表达的调节剂
|
CA3089117A1
(en)
|
2018-01-30 |
2019-08-08 |
Modernatx, Inc. |
Compositions and methods for delivery of agents to immune cells
|
EP3752612A4
(en)
|
2018-02-12 |
2021-11-10 |
Ionis Pharmaceuticals, Inc. |
MODIFIED COMPOUNDS AND USES THEREOF
|
US20210361761A1
(en)
|
2018-04-05 |
2021-11-25 |
Curevac Ag |
Novel yellow fever nucleic acid molecules for vaccination
|
US20210052506A1
(en)
*
|
2018-04-09 |
2021-02-25 |
Orgenesis Inc. |
Bioxomes particles, redoxomes, method and composition
|
US20210163928A1
(en)
|
2018-04-11 |
2021-06-03 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
EP4242307A3
(en)
|
2018-04-12 |
2023-12-27 |
MiNA Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
BR112020020933A2
(pt)
|
2018-04-17 |
2021-04-06 |
Curevac Ag |
Moléculas de rna de rsv inovadoras e composições para vacinação
|
EP3799604A4
(en)
|
2018-05-09 |
2022-09-07 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR REDUCING FXI EXPRESSION
|
EP3790607B1
(en)
|
2018-05-11 |
2023-12-27 |
Lupagen, Inc. |
Systems for closed loop, real-time modifications of patient cells
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
MA52709A
(fr)
|
2018-05-23 |
2021-03-31 |
Modernatx Inc |
Administration d'adn
|
US20220008338A1
(en)
|
2018-05-24 |
2022-01-13 |
Translate Bio, Inc. |
Thioester Cationic Lipids
|
JP7463006B2
(ja)
|
2018-05-30 |
2024-04-08 |
トランスレイト バイオ, インコーポレイテッド |
ステロイド性部分を含むカチオン性脂質
|
CN112672761A
(zh)
|
2018-05-30 |
2021-04-16 |
川斯勒佰尔公司 |
磷酸酯阳离子脂质
|
EP3801467A1
(en)
|
2018-05-30 |
2021-04-14 |
Translate Bio, Inc. |
Messenger rna vaccines and uses thereof
|
US20210206739A1
(en)
|
2018-05-30 |
2021-07-08 |
Translate Bio, Inc. |
Vitamin Cationic Lipids
|
PL3805198T3
(pl)
*
|
2018-06-08 |
2024-02-12 |
Fujifilm Corporation |
Związek, jego sól i cząstki lipidowe
|
US20210260178A1
(en)
|
2018-06-27 |
2021-08-26 |
Curevac Ag |
Novel lassa virus rna molecules and compositions for vaccination
|
CN112543629A
(zh)
|
2018-06-28 |
2021-03-23 |
阿斯利康(瑞典)有限公司 |
外泌体胞外囊泡及其使用方法
|
CN112638362A
(zh)
|
2018-07-23 |
2021-04-09 |
川斯勒佰尔公司 |
信使rna的干粉制剂
|
US20220184185A1
(en)
|
2018-07-25 |
2022-06-16 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
WO2020033748A1
(en)
|
2018-08-08 |
2020-02-13 |
Arcturus Therapeutics, Inc. |
Compositions and agents against nonalcoholic steatohepatitis
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
WO2020037102A1
(en)
|
2018-08-15 |
2020-02-20 |
University Of Florida Research Foundation, Inc. |
Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
|
CN112930396A
(zh)
|
2018-08-24 |
2021-06-08 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
KR20210091120A
(ko)
|
2018-08-29 |
2021-07-21 |
트랜슬레이트 바이오 인코포레이티드 |
Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정
|
US20220110966A1
(en)
|
2018-09-02 |
2022-04-14 |
Modernatx, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
US20220054610A1
(en)
|
2018-09-12 |
2022-02-24 |
University Of Florida Research Foundation, Inc. |
Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
|
EP3849594A2
(en)
|
2018-09-13 |
2021-07-21 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
|
CN113164561A
(zh)
|
2018-09-13 |
2021-07-23 |
摩登纳特斯有限公司 |
用于治疗糖原贮积病的编码葡萄糖-6-磷酸酶的多核苷酸
|
AU2019338535A1
(en)
|
2018-09-14 |
2021-04-15 |
Modernatx, Inc. |
Methods and compositions for treating cancer using mRNA therapeutics
|
WO2020056294A1
(en)
|
2018-09-14 |
2020-03-19 |
Translate Bio, Inc. |
Composition and methods for treatment of methylmalonic acidemia
|
US20220401584A1
(en)
|
2018-09-14 |
2022-12-22 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
TW202023573A
(zh)
|
2018-09-19 |
2020-07-01 |
美商Ionis製藥公司 |
Pnpla3表現之調節劑
|
EP3852728A1
(en)
|
2018-09-20 |
2021-07-28 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
EP3856233A1
(en)
|
2018-09-27 |
2021-08-04 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
AU2019351809A1
(en)
*
|
2018-10-01 |
2021-05-20 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
KR20210093232A
(ko)
|
2018-10-09 |
2021-07-27 |
더 유니버시티 오브 브리티시 콜롬비아 |
유기용매와 세제가 없는 형질감염 적격 소포를 포함하는 조성물과 시스템 및 관련 방법
|
CA3112837A1
(en)
|
2018-10-19 |
2020-04-23 |
Translate Bio, Inc. |
Pumpless encapsulation of messenger rna
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
AU2019374871A1
(en)
|
2018-11-09 |
2021-05-27 |
Translate Bio, Inc. |
PEG lipidoid compounds
|
MX2021005482A
(es)
|
2018-11-09 |
2021-09-08 |
Translate Bio Inc |
Lípidos de 2,5-dioxopiperazina con porciones éster, tioéster, disulfuro y anhidrido intercaladas.
|
US20220016265A1
(en)
|
2018-11-09 |
2022-01-20 |
Translate Bio, Inc. |
Messenger rna therapy for treatment of ocular diseases
|
WO2020097376A1
(en)
|
2018-11-09 |
2020-05-14 |
Translate Bio, Inc. |
Multi-peg lipid compounds
|
AU2019378763A1
(en)
|
2018-11-12 |
2021-06-03 |
Translate Bio, Inc. |
Methods for inducing immune tolerance
|
AU2019383413A1
(en)
|
2018-11-21 |
2021-05-27 |
Translate Bio, Inc. |
Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA
|
WO2020112908A2
(en)
|
2018-11-28 |
2020-06-04 |
Casebia Therapeutics Limited Liability Partnership |
OPTIMIZED mRNA ENCODING CAS9 FOR USE IN LNPs
|
EP4299750A2
(en)
|
2018-12-06 |
2024-01-03 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
EP3897702A2
(en)
|
2018-12-21 |
2021-10-27 |
CureVac AG |
Rna for malaria vaccines
|
JP2022516356A
(ja)
|
2019-01-07 |
2022-02-25 |
トランスレイト バイオ, インコーポレイテッド |
原発性線毛機能不全症の治療のための組成物および方法
|
US11453639B2
(en)
|
2019-01-11 |
2022-09-27 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
SG11202108098QA
(en)
|
2019-01-31 |
2021-08-30 |
Modernatx Inc |
Vortex mixers and associated methods, systems, and apparatuses thereof
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
WO2020161342A1
(en)
|
2019-02-08 |
2020-08-13 |
Curevac Ag |
Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
|
WO2020205473A1
(en)
|
2019-03-29 |
2020-10-08 |
Decerna Pharmaceuticals, Inc. |
Compositions and methods for the treatment of kras associated diseases or disorders
|
US20220204994A1
(en)
|
2019-04-05 |
2022-06-30 |
Precision Biosciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
EP3956303A1
(en)
|
2019-04-18 |
2022-02-23 |
Translate Bio, Inc. |
Cystine cationic lipids
|
EP3959195B1
(en)
|
2019-04-22 |
2023-11-08 |
Translate Bio, Inc. |
Thioester cationic lipids
|
EP3962521A1
(en)
|
2019-05-02 |
2022-03-09 |
University of Florida Research Foundation, Inc. |
Compositions for treatment of diffuse intrinsic pontine glioma
|
US20220257724A1
(en)
|
2019-05-03 |
2022-08-18 |
Translate Bio, Inc. |
Di-thioester cationic lipids
|
KR20220004675A
(ko)
|
2019-05-03 |
2022-01-11 |
다이서나 파마수이티컬, 인크. |
단축 센스 가닥을 갖는 이중 가닥 핵산 억제제 분자
|
MA55887A
(fr)
|
2019-05-07 |
2022-03-16 |
Modernatx Inc |
Microarn de cellules immunitaires exprimés de manière différentielle pour la régulation de l'expression de protéines
|
MA55896A
(fr)
|
2019-05-07 |
2022-03-16 |
Modernatx Inc |
Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser
|
WO2020227615A1
(en)
|
2019-05-08 |
2020-11-12 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
EP3965797A1
(en)
|
2019-05-08 |
2022-03-16 |
AstraZeneca AB |
Compositions for skin and wounds and methods of use thereof
|
JP2022533796A
(ja)
|
2019-05-22 |
2022-07-25 |
マサチューセッツ インスティテュート オブ テクノロジー |
環状rna組成物及び方法
|
EP3976593A1
(en)
|
2019-05-31 |
2022-04-06 |
Translate Bio, Inc. |
Macrocyclic lipids
|
WO2020247594A1
(en)
|
2019-06-04 |
2020-12-10 |
Cocoon Biotech Inc. |
Silk-based products, formulations, and methods of use
|
WO2020246581A1
(ja)
*
|
2019-06-07 |
2020-12-10 |
富士フイルム株式会社 |
脂質組成物
|
WO2020254535A1
(en)
|
2019-06-18 |
2020-12-24 |
Curevac Ag |
Rotavirus mrna vaccine
|
WO2020257716A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Tricine and citric acid lipids
|
WO2020257611A1
(en)
|
2019-06-21 |
2020-12-24 |
Translate Bio, Inc. |
Cationic lipids comprising an hydroxy moiety
|
WO2020263985A1
(en)
|
2019-06-24 |
2020-12-30 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
WO2020263883A1
(en)
|
2019-06-24 |
2020-12-30 |
Modernatx, Inc. |
Endonuclease-resistant messenger rna and uses thereof
|
US20230181483A1
(en)
|
2019-07-08 |
2023-06-15 |
Translate Bio, Inc. |
Improved mrna-loaded lipid nanoparticles and processes of making the same
|
EP3999097A1
(en)
|
2019-07-18 |
2022-05-25 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods for inducing full ablation of hematopoiesis
|
JP2022542839A
(ja)
|
2019-07-19 |
2022-10-07 |
フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー |
リコンビナーゼ組成物及び使用方法
|
CN114401748A
(zh)
|
2019-07-23 |
2022-04-26 |
川斯勒佰尔公司 |
负载mRNA的脂质纳米颗粒的稳定组合物及制备方法
|
US20220280639A1
(en)
|
2019-07-31 |
2022-09-08 |
Modernatx, Inc. |
Compositions and methods for delivery of rna interference agents to immune cells
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
AU2020325221A1
(en)
|
2019-08-07 |
2022-03-03 |
Modernatx, Inc. |
Compositions and methods for enhanced delivery of agents
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
CA3144902A1
(en)
|
2019-08-14 |
2022-01-19 |
Andreas Thess |
Rna combinations and compositions with decreased immunostimulatory properties
|
KR20220053599A
(ko)
|
2019-08-14 |
2022-04-29 |
아퀴타스 테라퓨틱스 인크. |
핵산을 전달하기 위한 개선된 지질 나노입자
|
EP4013784A1
(en)
|
2019-08-16 |
2022-06-22 |
Regeneron Pharmaceuticals, Inc. |
High concentration anti-c5 formulations
|
JP2022546597A
(ja)
|
2019-09-06 |
2022-11-04 |
ジェネレーション バイオ カンパニー |
閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法
|
CA3154618A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
BR112022005028A2
(pt)
|
2019-09-20 |
2022-07-05 |
Ractigen Therapeutics |
Molécula de ácido nucleico para tratamento de trombocitopenia e uso da mesma
|
WO2021055609A1
(en)
|
2019-09-20 |
2021-03-25 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
EP4041894A1
(en)
|
2019-09-23 |
2022-08-17 |
Omega Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION
|
WO2021061707A1
(en)
|
2019-09-23 |
2021-04-01 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein b (apob) gene expression
|
CN114728017A
(zh)
|
2019-10-14 |
2022-07-08 |
阿斯利康(瑞典)有限公司 |
Pnpla3表达的调节剂
|
WO2021076811A1
(en)
|
2019-10-15 |
2021-04-22 |
Moderna TX, Inc. |
Mrnas encoding granulocyte-macrophage colony stimulating factor for treating parkinson's disease
|
EP4045652A1
(en)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member irna compositions and methods of use thereof
|
US20210145860A1
(en)
|
2019-10-21 |
2021-05-20 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
KR20220084399A
(ko)
|
2019-10-22 |
2022-06-21 |
알닐람 파마슈티칼스 인코포레이티드 |
보체 성분 C3 iRNA 조성물 및 이의 사용 방법
|
CN111205994B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株具核梭杆菌动物亚种菌株及其应用
|
CN110903998B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株肠道分离的具核梭杆菌文氏亚种菌株及其应用
|
CN111004738B
(zh)
*
|
2019-10-23 |
2021-09-21 |
上海市第十人民医院 |
一株具核梭杆菌多形亚种分离株及其应用
|
EP4048691A1
(en)
|
2019-10-25 |
2022-08-31 |
Regeneron Pharmaceuticals, Inc. |
Dosing regimens for treating or preventing c5-associated diseases
|
AR120341A1
(es)
|
2019-11-01 |
2022-02-09 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
PE20230179A1
(es)
|
2019-11-13 |
2023-02-01 |
Alnylam Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt)
|
EP4328309A2
(en)
|
2019-11-15 |
2024-02-28 |
FUJIFILM Corporation |
Lipid composition
|
EP4061945A1
(en)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
JPWO2021117770A1
(ru)
*
|
2019-12-10 |
2021-06-17 |
|
|
WO2021117769A1
(ja)
*
|
2019-12-10 |
2021-06-17 |
富士フイルム株式会社 |
医薬組成物及び処置剤
|
WO2021119226A1
(en)
|
2019-12-13 |
2021-06-17 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
CN115515559A
(zh)
|
2019-12-20 |
2022-12-23 |
翻译生物公司 |
信使rna的直肠递送
|
AU2020405214A1
(en)
|
2019-12-20 |
2022-08-11 |
Translate Bio, Inc. |
Improved process of preparing mRNA-loaded lipid nanoparticles
|
JP2023507465A
(ja)
|
2019-12-20 |
2023-02-22 |
キュアバック エスイー |
核酸を送達するための脂質ナノ粒子
|
CN110974954B
(zh)
*
|
2019-12-24 |
2021-03-16 |
珠海丽凡达生物技术有限公司 |
一种用于增强核酸疫苗免疫效果的脂质纳米颗粒及其制备方法
|
AU2021205337A1
(en)
|
2020-01-10 |
2022-07-21 |
Modernatx, Inc. |
Methods of making tolerogenic dendritic cells
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
IL294599A
(en)
|
2020-01-15 |
2022-09-01 |
Dicerna Pharmaceuticals Inc |
Methylene phosphonate nucleic acids and their analogs
|
TW202139976A
(zh)
|
2020-01-31 |
2021-11-01 |
美商現代公司 |
製備脂質奈米顆粒之方法
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
IL293571A
(en)
|
2020-02-04 |
2022-08-01 |
Curevac Ag |
Corona virus vaccine
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
AU2021224778A1
(en)
|
2020-02-18 |
2022-09-29 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
|
CN115427021A
(zh)
|
2020-02-25 |
2022-12-02 |
翻译生物公司 |
制备负载mrna的脂质纳米颗粒的改进方法
|
US20220064638A1
(en)
|
2020-02-28 |
2022-03-03 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating smn2
|
CA3174708A1
(en)
*
|
2020-03-04 |
2021-09-10 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
JP2023516095A
(ja)
|
2020-03-06 |
2023-04-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
JP2023517644A
(ja)
|
2020-03-09 |
2023-04-26 |
アークトゥラス・セラピューティクス・インコーポレイテッド |
コロナウイルスワクチン組成物及び方法
|
JP2023517326A
(ja)
|
2020-03-11 |
2023-04-25 |
オメガ セラピューティクス, インコーポレイテッド |
フォークヘッドボックスp3(foxp3)遺伝子発現をモジュレートするための組成物および方法
|
CN115667531A
(zh)
|
2020-03-24 |
2023-01-31 |
世代生物公司 |
非病毒DNA载体和其用于表达戈谢(Gaucher)治疗剂的用途
|
JP2023520764A
(ja)
|
2020-03-24 |
2023-05-19 |
ジェネレーション バイオ カンパニー |
第ix因子治療薬を発現するための非ウイルス性dnaベクター及びその使用
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
WO2021202772A1
(en)
|
2020-04-01 |
2021-10-07 |
University Of Florida Research Foundation, Incorporated |
Multilamellar rna nanoparticle vaccine against sars-cov-2
|
EP4133078A1
(en)
|
2020-04-06 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing myoc expression
|
TW202204617A
(zh)
|
2020-04-07 |
2022-02-01 |
美商艾爾妮蘭製藥公司 |
用於靜默scn9a表現之組合物及方法
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
EP4143319A1
(en)
|
2020-04-27 |
2023-03-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
EP4146680A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
KR20230008801A
(ko)
|
2020-05-07 |
2023-01-16 |
트랜슬레이트 바이오 인코포레이티드 |
Sars-cov-2 항원을 암호화하는 최적화된 뉴클레오티드 서열
|
US20230181619A1
(en)
|
2020-05-07 |
2023-06-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
EP4149435A1
(en)
|
2020-05-14 |
2023-03-22 |
Modernatx, Inc. |
Lnp compositions comprising an mrna therapeutic and an effector molecule
|
US20230226219A1
(en)
|
2020-05-14 |
2023-07-20 |
Translate Bio, Inc. |
Peg lipidoid compounds
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
EP4149425A1
(en)
|
2020-05-15 |
2023-03-22 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
KR20230022415A
(ko)
|
2020-05-18 |
2023-02-15 |
맥스 바이올로지 컴퍼니 리미티드 |
지질-중합체 조성물 및 사용 방법
|
EP4153223A1
(en)
|
2020-05-20 |
2023-03-29 |
Flagship Pioneering Innovations VI, LLC |
Immunogenic compositions and uses thereof
|
IL298362A
(en)
|
2020-05-20 |
2023-01-01 |
Flagship Pioneering Innovations Vi Llc |
Corona virus antigen compositions and their uses
|
WO2021243207A1
(en)
|
2020-05-28 |
2021-12-02 |
Modernatx, Inc. |
Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
|
CA3182026A1
(en)
|
2020-05-29 |
2021-12-02 |
Flagship Pioneering Innovations Vi, Llc. |
Trem compositions and methods relating thereto
|
CN116322758A
(zh)
|
2020-05-29 |
2023-06-23 |
库尔维科欧洲股份公司 |
基于核酸的组合疫苗
|
AU2021278984A1
(en)
|
2020-05-29 |
2022-11-17 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods relating thereto
|
US20230235298A1
(en)
|
2020-06-01 |
2023-07-27 |
Modernatx, Inc. |
Phenylalanine hydroxylase variants and uses thereof
|
WO2021247535A1
(en)
|
2020-06-01 |
2021-12-09 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
CA3184289A1
(en)
|
2020-06-18 |
2021-12-23 |
Alnylam Pharmaceuticals, Inc. |
Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
|
US20230242908A1
(en)
|
2020-06-23 |
2023-08-03 |
Modernatx, Inc. |
Lnp compositions comprising mrna therapeutics with extended half-life
|
WO2022006527A1
(en)
|
2020-07-02 |
2022-01-06 |
Maritime Therapeutics, Inc. |
Compositions and methods for reverse gene therapy
|
TW202216190A
(zh)
|
2020-07-08 |
2022-05-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
抗hbv之rna複製子疫苗
|
EP4179091A1
(en)
|
2020-07-10 |
2023-05-17 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Methods and compositions for treating epilepsy
|
KR20230040353A
(ko)
|
2020-07-17 |
2023-03-22 |
그린라이트 바이오사이언시스, 아이엔씨. |
유전 장애를 위한 핵산 치료제
|
MX2023001109A
(es)
|
2020-07-27 |
2023-04-24 |
Anjarium Biosciences Ag |
Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
|
US20230272052A1
(en)
|
2020-07-31 |
2023-08-31 |
CureVac SE |
Nucleic acid encoded antibody mixtures
|
IL300283A
(en)
|
2020-08-04 |
2023-04-01 |
Dicerna Pharmaceuticals Inc |
Systemic administration of oligonucleotides
|
BR112023002071A2
(pt)
|
2020-08-06 |
2023-05-02 |
Modernatx Inc |
Métodos para preparar nanopartículas lipídicas
|
CA3170743A1
(en)
|
2020-08-31 |
2022-03-03 |
Susanne RAUCH |
Multivalent nucleic acid based coronavirus vaccines
|
IL300947A
(en)
|
2020-09-03 |
2023-04-01 |
Flagship Pioneering Innovations Vi Llc |
Immunogenic compositions and uses thereof
|
WO2022054955A1
(ja)
|
2020-09-14 |
2022-03-17 |
富士フイルム株式会社 |
脂質組成物
|
WO2022066678A1
(en)
|
2020-09-23 |
2022-03-31 |
Translate Bio, Inc. |
Tes-based cationic lipids
|
WO2022066916A1
(en)
|
2020-09-23 |
2022-03-31 |
Translate Bio, Inc. |
Piperazine-based cationic lipids
|
EP4217489A1
(en)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
JP2023545924A
(ja)
*
|
2020-09-25 |
2023-11-01 |
ディーエヌエーアールエックス |
対象における生体分子を発現するためのシステム及び方法
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法
|
AU2021358490A1
(en)
|
2020-10-05 |
2023-06-01 |
Max Biology Co. Ltd. |
Cannabinoid-containing compositions and use for treating and preventing diseases
|
JP2023544197A
(ja)
|
2020-10-06 |
2023-10-20 |
トランスレイト バイオ, インコーポレイテッド |
脂質ナノ粒子の改善された方法および製剤
|
WO2022076547A1
(en)
|
2020-10-07 |
2022-04-14 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
AU2021361986A1
(en)
|
2020-10-12 |
2023-06-15 |
Translate Bio, Inc. |
Improved process of preparing mrna-loaded lipid nanoparticles
|
US20220133631A1
(en)
|
2020-10-12 |
2022-05-05 |
Translate Bio, Inc. |
Process of preparing ice-based lipid nanoparticles
|
EP4232581A1
(en)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
EP4232582A1
(en)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
EP4240326A1
(en)
|
2020-11-09 |
2023-09-13 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
WO2022104131A1
(en)
|
2020-11-13 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
AU2021380809A1
(en)
|
2020-11-13 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4136092A4
(en)
|
2020-11-18 |
2023-10-11 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING ANGIOTENSINOGEN EXPRESSION
|
US20220287966A1
(en)
|
2020-11-25 |
2022-09-15 |
Translate Bio, Inc. |
Stable Liquid Lipid Nanoparticle Formulations
|
WO2022112855A1
(en)
|
2020-11-27 |
2022-06-02 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
US20230242474A1
(en)
|
2020-11-27 |
2023-08-03 |
Guangzhou Ribobio Co., Ltd |
Lipid compound and the composition thereof
|
US20230015616A1
(en)
|
2020-11-30 |
2023-01-19 |
Argorna Pharmaceuticals Ltd |
Coronavirus vaccines and uses thereof
|
EP4256053A1
(en)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
GB2603454A
(en)
|
2020-12-09 |
2022-08-10 |
Ucl Business Ltd |
Novel therapeutics for the treatment of neurodegenerative disorders
|
WO2022137133A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Rna vaccine against sars-cov-2 variants
|
CA3171051A1
(en)
|
2020-12-22 |
2022-06-30 |
Curevac Ag |
Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration
|
BR112023012377A2
(pt)
|
2020-12-23 |
2023-10-24 |
Flagship Pioneering Innovations Vi Llc |
Composições de trems modificadas e usos das mesmas
|
AU2021412833A1
(en)
|
2020-12-28 |
2023-07-06 |
Arcturus Therapeutics, Inc. |
Transcription activator-like effector nucleases (talens) targeting hbv
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
CN116981692A
(zh)
|
2021-01-14 |
2023-10-31 |
翻译生物公司 |
递送mRNA编码的抗体的方法和组合物
|
CA3170747A1
(en)
|
2021-01-27 |
2022-08-04 |
Moritz THRAN |
Method of reducing the immunostimulatory properties of in vitro transcribed rna
|
WO2022168884A1
(ja)
|
2021-02-04 |
2022-08-11 |
塩野義製薬株式会社 |
カチオン性脂質
|
AU2021425941A1
(en)
|
2021-02-08 |
2023-08-17 |
The Board Of Regents Of The University Of Texas System |
Unsaturated dendrimers compositions,related formulations, and methods of use thereof
|
CA3210763A1
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
JP2024506908A
(ja)
|
2021-02-12 |
2024-02-15 |
モデルナティエックス インコーポレイテッド |
インビボ療法のためのペイロードを含むlnp組成物
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
EP4298220A1
(en)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prion protein (prnp) irna compositions and methods of use thereof
|
TW202302847A
(zh)
|
2021-02-26 |
2023-01-16 |
美商艾拉倫製藥股份有限公司 |
己酮糖激酶(KHK)iRNA組成物及其使用方法
|
BR112023016903A2
(pt)
|
2021-02-26 |
2023-10-10 |
Ethris Gmbh |
Formulação de suspensão aquosa para formação de aerossol, nebulizador, e, aerossol
|
KR20230150843A
(ko)
|
2021-03-04 |
2023-10-31 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 이의 사용 방법
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
WO2022204370A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
WO2022204371A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
WO2022204369A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
JP2024511206A
(ja)
|
2021-03-26 |
2024-03-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
TW202305133A
(zh)
|
2021-03-26 |
2023-02-01 |
英商米納治療有限公司 |
Tmem173 sarna組合物及其使用方法
|
KR20230162024A
(ko)
|
2021-03-29 |
2023-11-28 |
알닐람 파마슈티칼스 인코포레이티드 |
헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법
|
CA3171429A1
(en)
|
2021-03-31 |
2022-09-30 |
Alexander SCHWENGER |
Syringes containing pharmaceutical compositions comprising rna
|
WO2022212784A1
(en)
|
2021-03-31 |
2022-10-06 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
EP4314293A1
(en)
|
2021-04-01 |
2024-02-07 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
WO2022212711A2
(en)
|
2021-04-01 |
2022-10-06 |
Modernatx, Inc. |
Methods for identification and ratio determination of rna species in multivalent rna compositions
|
TW202309002A
(zh)
|
2021-04-15 |
2023-03-01 |
美商轉譯生技公司 |
基於「古德」緩衝液的陽離子脂質
|
JP2024515668A
(ja)
|
2021-04-19 |
2024-04-10 |
トランスレイト バイオ, インコーポレイテッド |
Mrnaの送達のための改善された組成物
|
WO2022223556A1
(en)
|
2021-04-20 |
2022-10-27 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
|
EP4326241A1
(en)
|
2021-04-23 |
2024-02-28 |
ModernaTX, Inc. |
Isoquinoline-stabilized lipid nanoparticle formulations
|
EP4326227A1
(en)
|
2021-04-23 |
2024-02-28 |
ModernaTX, Inc. |
Stabilized formulations
|
WO2022231999A1
(en)
|
2021-04-26 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
|
KR20240011714A
(ko)
|
2021-04-27 |
2024-01-26 |
제너레이션 바이오 컴퍼니 |
치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
|
EP4329884A1
(en)
|
2021-04-27 |
2024-03-06 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
EP4329731A1
(en)
|
2021-04-29 |
2024-03-06 |
ModernaTX, Inc. |
Lyophilization methods for preparing lipid formulated therapeutics
|
CA3171589A1
(en)
|
2021-05-03 |
2022-11-03 |
Moritz THRAN |
Improved nucleic acid sequence for cell type specific expression
|
EP4337177A1
(en)
|
2021-05-11 |
2024-03-20 |
Modernatx, Inc. |
Non-viral delivery of dna for prolonged polypeptide expression in vivo
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
WO2022246020A1
(en)
|
2021-05-19 |
2022-11-24 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CN113546180A
(zh)
*
|
2021-05-25 |
2021-10-26 |
重庆医科大学 |
一种具有心肌靶向性的基因递送载体及其制备方法
|
AU2022282812A1
(en)
*
|
2021-05-28 |
2023-11-09 |
Nanovation Therapeutics Inc. |
Mc3-type lipids and use thereof in the preparation of lipid nanoparticles
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256395A1
(en)
|
2021-06-02 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
AR126000A1
(es)
|
2021-06-04 |
2023-08-30 |
Alnylam Pharmaceuticals Inc |
Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
WO2022260772A1
(en)
*
|
2021-06-09 |
2022-12-15 |
Carnegie Mellon University |
Lipid nanoparticle formulations for gastrointestinal delivery
|
WO2022266083A2
(en)
|
2021-06-15 |
2022-12-22 |
Modernatx, Inc. |
Engineered polynucleotides for cell-type or microenvironment-specific expression
|
WO2022271776A1
(en)
|
2021-06-22 |
2022-12-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
KR102516680B1
(ko)
*
|
2021-06-24 |
2023-04-03 |
주식회사 테르나테라퓨틱스 |
지질 나노 입자 및 그 제조방법
|
WO2022270941A1
(ko)
*
|
2021-06-24 |
2022-12-29 |
주식회사 테르나테라퓨틱스 |
지질 나노 입자 및 그 제조방법
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
CA3225469A1
(en)
|
2021-06-30 |
2023-01-05 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
WO2023278811A1
(en)
|
2021-07-01 |
2023-01-05 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
CN117881395A
(zh)
|
2021-07-01 |
2024-04-12 |
翻译生物公司 |
用于递送mRNA的组合物
|
WO2023283359A2
(en)
|
2021-07-07 |
2023-01-12 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
WO2023287751A1
(en)
|
2021-07-12 |
2023-01-19 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
IL309897A
(en)
|
2021-07-21 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Target gene IRNA compositions associated with a metabolic disorder and methods of using them
|
KR20240037293A
(ko)
|
2021-07-23 |
2024-03-21 |
알닐람 파마슈티칼스 인코포레이티드 |
베타-카테닌(CTNNB1) iRNA 조성물 및 이의 사용 방법
|
WO2023009547A1
(en)
|
2021-07-26 |
2023-02-02 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and uses thereof
|
WO2023009499A1
(en)
|
2021-07-27 |
2023-02-02 |
Modernatx, Inc. |
Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease type 1a (gsd1a)
|
WO2023008415A1
(ja)
|
2021-07-27 |
2023-02-02 |
STAND Therapeutics株式会社 |
ペプチドタグおよび当該ペプチドタグをコードする核酸
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
CA3171750A1
(en)
|
2021-07-30 |
2023-02-02 |
Tim SONNTAG |
Mrnas for treatment or prophylaxis of liver diseases
|
WO2023014649A1
(en)
|
2021-08-02 |
2023-02-09 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography of mrna encapsulated in lipid nanoparticles for mrna purity assessment
|
AU2022323090A1
(en)
|
2021-08-03 |
2024-02-01 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
WO2023015261A1
(en)
|
2021-08-04 |
2023-02-09 |
Modernatx, Inc. |
Mrnas encoding chimeric metabolic reprogramming polypeptides and uses thereof
|
WO2023014765A1
(en)
|
2021-08-04 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
WO2023014974A1
(en)
|
2021-08-06 |
2023-02-09 |
University Of Iowa Research Foundation |
Double stranded mrna vaccines
|
WO2023018773A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Lipid nanoparticle formulations and methods of synthesis thereof
|
WO2023019181A1
(en)
|
2021-08-11 |
2023-02-16 |
Modernatx, Inc. |
Sars-cov-2 lipid nanoparticle vaccine formulations
|
TW202334413A
(zh)
|
2021-08-13 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
第十二因子(F12)iRNA組成物及其使用方法
|
CA3229889A1
(en)
|
2021-09-03 |
2023-03-09 |
Glaxosmithkline Biologicals Sa |
Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids
|
IL309505A
(en)
|
2021-09-03 |
2024-02-01 |
CureVac SE |
Lipid nanoparticles for nucleic acid delivery
|
WO2023031392A2
(en)
|
2021-09-03 |
2023-03-09 |
CureVac SE |
Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
|
WO2023044006A1
(en)
|
2021-09-17 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Compositions and methods for producing circular polyribonucleotides
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
CA3232420A1
(en)
|
2021-09-20 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
WO2023056044A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
WO2023056401A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Rna formulations for high volume distribution, and methods of using the same for treating a disease or condition caused by or associated with human cytomegalovirus
|
WO2023064469A1
(en)
|
2021-10-13 |
2023-04-20 |
Modernatx, Inc. |
Compositions of mrna-encoded il15 fusion proteins and methods of use thereof
|
AU2022364838A1
(en)
|
2021-10-15 |
2024-04-11 |
Alnylam Pharmaceuticals, Inc. |
Extra-hepatic delivery irna compositions and methods of use thereof
|
WO2023069895A1
(en)
|
2021-10-18 |
2023-04-27 |
Modernatx, Inc. |
Markerless dna production
|
TW202322826A
(zh)
|
2021-10-18 |
2023-06-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物及方法
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023073534A1
(en)
|
2021-10-26 |
2023-05-04 |
Astrazeneca Ab |
Novel lipids for delivery of nucleic acid segments
|
WO2023073228A1
(en)
|
2021-10-29 |
2023-05-04 |
CureVac SE |
Improved circular rna for expressing therapeutic proteins
|
TW202333749A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
補體因子b(cfb)irna組成物及其使用方法
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2023077170A1
(en)
|
2021-11-01 |
2023-05-04 |
Modernatx, Inc. |
Polynucleotides encoding integrin beta-6 and methods of use thereof
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023086893A1
(en)
|
2021-11-10 |
2023-05-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
KR20230068047A
(ko)
|
2021-11-10 |
2023-05-17 |
주식회사 에스엠엘바이오팜 |
트레할로즈 유도체 및 신규 구조 유지 화합물을 포함하는 핵산 의약품 전달용 지질나노입자의 약학 조성물
|
WO2023092060A1
(en)
|
2021-11-18 |
2023-05-25 |
Cornell University |
Microrna-dependent mrna switches for tissue-specific mrna-based therapies
|
US20230181482A1
(en)
|
2021-11-18 |
2023-06-15 |
Astrazeneca Ab |
Lipids for delivery of nucleic acid segments
|
WO2023092151A1
(en)
*
|
2021-11-22 |
2023-05-25 |
Ohio State Innovation Foundation |
Compositions and methods for the treatment of neurodegenerative disorders
|
WO2023096963A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Varicella-zoster virus immunogen compositions and their uses
|
WO2023096990A1
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovation Vi, Llc |
Coronavirus immunogen compositions and their uses
|
WO2023097003A2
(en)
|
2021-11-24 |
2023-06-01 |
Flagship Pioneering Innovations Vi, Llc |
Immunogenic compositions and their uses
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
WO2023107999A2
(en)
|
2021-12-08 |
2023-06-15 |
Modernatx, Inc. |
Herpes simplex virus mrna vaccines
|
GB202117758D0
(en)
|
2021-12-09 |
2022-01-26 |
Ucl Business Ltd |
Therapeutics for the treatment of neurodegenerative disorders
|
WO2023114307A1
(en)
|
2021-12-15 |
2023-06-22 |
Modernatx, Inc. |
Determination of encapsulation efficiency of lipid nanoparticles
|
WO2023114889A1
(en)
|
2021-12-16 |
2023-06-22 |
Modernatx, Inc. |
Processes for preparing lipid nanoparticles
|
TW202340461A
(zh)
|
2021-12-22 |
2023-10-16 |
美商旗艦先鋒創新有限責任公司 |
用於純化多核糖核苷酸之組成物和方法
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
TW202342064A
(zh)
|
2021-12-23 |
2023-11-01 |
美商旗艦先鋒創新有限責任公司 |
編碼抗融合多肽之環狀多核糖核苷酸
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
CN114044741B
(zh)
|
2022-01-13 |
2022-04-15 |
北京悦康科创医药科技股份有限公司 |
一种阳离子脂质化合物、包含其的组合物及用途
|
WO2023135273A2
(en)
|
2022-01-14 |
2023-07-20 |
Anjarium Biosciences Ag |
Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
|
WO2023135298A1
(en)
|
2022-01-17 |
2023-07-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of inducing cell death of a population of solid tumor cells
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023144193A1
(en)
|
2022-01-25 |
2023-08-03 |
CureVac SE |
Mrnas for treatment of hereditary tyrosinemia type i
|
WO2023147090A1
(en)
|
2022-01-27 |
2023-08-03 |
BioNTech SE |
Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods
|
WO2023144330A1
(en)
|
2022-01-28 |
2023-08-03 |
CureVac SE |
Nucleic acid encoded transcription factor inhibitors
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023152365A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of the 15-lipoxygenase for the treatment of lymphedema
|
TW202345864A
(zh)
|
2022-02-18 |
2023-12-01 |
美商現代公司 |
編碼檢查點癌症疫苗之mRNA及其用途
|
WO2023161350A1
(en)
|
2022-02-24 |
2023-08-31 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
TW202345835A
(zh)
|
2022-03-16 |
2023-12-01 |
美商轉譯生技公司 |
非對稱的基於哌嗪之陽離子脂質
|
WO2023177904A1
(en)
|
2022-03-18 |
2023-09-21 |
Modernatx, Inc. |
Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
WO2023193002A1
(en)
|
2022-04-01 |
2023-10-05 |
Modernatx, Inc. |
Cross mixers for lipid nanoparticle production, and methods of operating the same
|
WO2023196399A1
(en)
|
2022-04-06 |
2023-10-12 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding argininosuccinate lyase for the treatment of argininosuccinic aciduria
|
WO2023196988A1
(en)
|
2022-04-07 |
2023-10-12 |
Modernatx, Inc. |
Methods of use of mrnas encoding il-12
|
WO2023196634A2
(en)
|
2022-04-08 |
2023-10-12 |
Flagship Pioneering Innovations Vii, Llc |
Vaccines and related methods
|
WO2023198857A1
(en)
|
2022-04-13 |
2023-10-19 |
Sanofi |
"good" buffer-based cationic lipids
|
WO2023200893A1
(en)
*
|
2022-04-13 |
2023-10-19 |
Oregon State University |
Small molecule enhancers of antisense oligo activity
|
WO2023201296A1
(en)
|
2022-04-15 |
2023-10-19 |
Modernatx, Inc. |
Ribosomal engagement potency assay
|
WO2023212696A1
(en)
|
2022-04-29 |
2023-11-02 |
Modernatx, Inc. |
Lyophilized human cytomegalovirus vaccines
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023220083A1
(en)
|
2022-05-09 |
2023-11-16 |
Flagship Pioneering Innovations Vi, Llc |
Trem compositions and methods of use for treating proliferative disorders
|
WO2023218420A1
(en)
|
2022-05-13 |
2023-11-16 |
Janssen Pharmaceuticals, Inc. |
Mrna compositions for inducing latent hiv-1 reversal
|
WO2023220729A2
(en)
|
2022-05-13 |
2023-11-16 |
Flagship Pioneering Innovations Vii, Llc |
Double stranded dna compositions and related methods
|
WO2023220734A2
(en)
*
|
2022-05-13 |
2023-11-16 |
The Trustees Of The University Of Pennsylvania |
Bisphosphonate lipids, lipid nanoparticle compositions comprising the same, and methods of use thereof for targeted delivery
|
WO2023227608A1
(en)
|
2022-05-25 |
2023-11-30 |
Glaxosmithkline Biologicals Sa |
Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
|
WO2023230601A1
(en)
|
2022-05-27 |
2023-11-30 |
Beam Therapeutics Inc. |
Identification of nanoparticles for preferential tissue or cell targeting
|
WO2023239756A1
(en)
|
2022-06-07 |
2023-12-14 |
Generation Bio Co. |
Lipid nanoparticle compositions and uses thereof
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
CN117263818A
(zh)
*
|
2022-06-14 |
2023-12-22 |
杭州高田生物医药有限公司 |
阳离子脂质化合物及其制备方法和应用
|
WO2023242817A2
(en)
|
2022-06-18 |
2023-12-21 |
Glaxosmithkline Biologicals Sa |
Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2
|
WO2023250112A1
(en)
|
2022-06-22 |
2023-12-28 |
Flagship Pioneering Innovations Vi, Llc |
Compositions of modified trems and uses thereof
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024015890A1
(en)
|
2022-07-13 |
2024-01-18 |
Modernatx, Inc. |
Norovirus mrna vaccines
|
WO2024023034A1
(en)
|
2022-07-25 |
2024-02-01 |
Institut National de la Santé et de la Recherche Médicale |
Use of apelin for the treatment of lymphedema
|
WO2024026254A1
(en)
|
2022-07-26 |
2024-02-01 |
Modernatx, Inc. |
Engineered polynucleotides for temporal control of expression
|
WO2024026475A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
|
WO2024026487A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
|
WO2024026482A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
|
WO2024030856A2
(en)
|
2022-08-01 |
2024-02-08 |
Flagship Pioneering Innovations Vii, Llc |
Immunomodulatory proteins and related methods
|
WO2024030369A1
(en)
|
2022-08-01 |
2024-02-08 |
Modernatx, Inc. |
Extraction-less reverse phase (rp) chromatography for mrna purity assessment
|
WO2024035952A1
(en)
|
2022-08-12 |
2024-02-15 |
Remix Therapeutics Inc. |
Methods and compositions for modulating splicing at alternative splice sites
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
US20240067968A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
WO2024044147A1
(en)
|
2022-08-23 |
2024-02-29 |
Modernatx, Inc. |
Methods for purification of ionizable lipids
|
EP4327829A1
(en)
|
2022-08-26 |
2024-02-28 |
Ethris GmbH |
Stabilization of lipid or lipidoid nanoparticle suspensions
|
WO2024042236A1
(en)
|
2022-08-26 |
2024-02-29 |
Ethris Gmbh |
Stable lipid or lipidoid nanoparticle suspensions
|
WO2024050483A1
(en)
|
2022-08-31 |
2024-03-07 |
Modernatx, Inc. |
Variant strain-based coronavirus vaccines and uses thereof
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064931A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of liver stage antigens and related methods
|
WO2024064934A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of plasmodium csp antigens and related methods
|
WO2024063789A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024063788A1
(en)
|
2022-09-23 |
2024-03-28 |
BioNTech SE |
Compositions for delivery of malaria antigens and related methods
|
WO2024068545A1
(en)
|
2022-09-26 |
2024-04-04 |
Glaxosmithkline Biologicals Sa |
Influenza virus vaccines
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|